{"id":49327,"date":"2012-03-29T08:04:22","date_gmt":"2012-03-29T08:04:22","guid":{"rendered":"https:\/\/mppt.hu\/project\/2012-marcius-xiv-evfolyam-1-szam\/"},"modified":"2020-10-29T15:40:43","modified_gmt":"2020-10-29T15:40:43","slug":"2012-marcius-xiv-evfolyam-1-szam","status":"publish","type":"project","link":"https:\/\/mppt.hu\/en\/project\/2012-marcius-xiv-evfolyam-1-szam\/","title":{"rendered":"Volume 14, Issue 1, March 2012"},"content":{"rendered":"<p>[et_pb_section fb_built=&#8221;1&#8243; _builder_version=&#8221;3.22.7&#8243; custom_padding=&#8221;||5px|||&#8221;][et_pb_row _builder_version=&#8221;3.25&#8243;][et_pb_column type=&#8221;4_4&#8243; _builder_version=&#8221;3.25&#8243; custom_padding=&#8221;|||&#8221; custom_padding__hover=&#8221;|||&#8221;][et_pb_text _builder_version=&#8221;3.27.4&#8243;]<\/p>\n<h4 style=\"text-align: center;\">VOLUME 14, ISSUE 1, MARCH 2012<\/h4>\n<p>[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=&#8221;1&#8243; specialty=&#8221;on&#8221; _builder_version=&#8221;3.22.3&#8243; custom_padding=&#8221;24px|0px|25px|0px|false|false&#8221;][et_pb_column type=&#8221;3_4&#8243; specialty_columns=&#8221;3&#8243; _builder_version=&#8221;3.25&#8243; custom_padding=&#8221;|||&#8221; custom_padding__hover=&#8221;|||&#8221;][et_pb_row_inner _builder_version=&#8221;3.25&#8243;][et_pb_column_inner saved_specialty_column_type=&#8221;3_4&#8243; _builder_version=&#8221;3.25&#8243; custom_padding=&#8221;|||&#8221; custom_padding__hover=&#8221;|||&#8221;][et_pb_blurb title=&#8221;Psychosocial changes in six months of buprenorphine\/naloxone substitution treatment&#8221; url=&#8221;https:\/\/mppt.hu\/magazin\/pdf\/xiv-evfolyam-1-szam\/petke%20web.pdf&#8221; url_new_window=&#8221;on&#8221; image=&#8221;https:\/\/mppt.hu\/wp-content\/uploads\/2019\/04\/pdf.png&#8221; icon_placement=&#8221;left&#8221; image_max_width=&#8221;105%&#8221; content_max_width=&#8221;1100px&#8221; _builder_version=&#8221;3.22.7&#8243; header_font=&#8221;||||||||&#8221; header_font_size=&#8221;17px&#8221; header_line_height=&#8221;1.3em&#8221; body_font=&#8221;||on||||||&#8221; body_line_height=&#8221;1.3em&#8221; link_option_url=&#8221;https:\/\/mppt.hu\/magazin\/pdf\/xiv-evfolyam-1-szam\/petke web.pdf&#8221; link_option_url_new_window=&#8221;on&#8221;]<\/p>\n<p>Zsolt Petke, J\u00f3zsef Csorba, Judit M\u00e9sz\u00e1ros, Istv\u00e1n Vingender, Judit Farkas, Zsolt Demetrovics, Zsuzsanna Kov\u00e1cs, Zsuzsa Menczel, Zolt\u00e1n Pataki, P\u00e9ter Simor, Anna Havasi, Katalin Melles, Ferenc\u00a0 M\u00e1rv\u00e1nyk\u00f6vi and J\u00f3zsef R\u00e1cz<\/p>\n<p>[\/et_pb_blurb][et_pb_toggle title=&#8221;Abstract&#8221; closed_toggle_text_color=&#8221;#000000&#8243; closed_toggle_background_color=&#8221;rgba(0,0,0,0)&#8221; icon_color=&#8221;#0c71c3&#8243; _builder_version=&#8221;4.6.6&#8243; title_font=&#8221;|600|||||||&#8221; title_letter_spacing=&#8221;1px&#8221; text_orientation=&#8221;justified&#8221; custom_padding=&#8221;0px||10px&#8221; border_width_all=&#8221;0px&#8221; border_width_bottom=&#8221;1px&#8221;]<\/p>\n<p class=\"art\">Aims: The main target of our research was to measure the changes in psychological symptoms<br \/> (anxiety, depression, craving) of patients receiving buprenorphine-naloxone substitution<br \/> treatment for six months, and the evaluation of the changes using the clients\u2019 dependency<br \/> parameters (ASI). Methods: The level of dependency was investigated using the Addicton<br \/> Severity Index (ASI). The psychiatric symptoms related to Axis I and II disorders were examined<br \/> using the Structured Clinical Interview for DSM-IV, SCID I and SCID II. The degree of craving<br \/> was measured using the Heroin Craving Questionnaire, the assessment of the symptoms of<br \/> depression using BDI and HAM-D, recorded by the medical attendant of the patient. To survey<br \/> the extent of anxiety, we used STAI-S, and HAM-A. All patients receiving Suboxone therapy<br \/> in Hungary between November 2007 and April 2008 were included in the study (n=80). During this time, Suboxone therapy was available in 6 locations. Results: We found significant<br \/> improvement in almost all observed fields of behavioural and symptomatic dimensions during the first month. The only exception was the dimension of subsistence\/livelihood of ASI,<br \/> the changes were only at the tendency level. During the next five months of therapy, there<br \/> was no further sign of improvement or decline in the observed fields, the only exception was<br \/> again the subsistence\/livelihood dimension of the ASI. Conclusions: Our results indicate that<br \/> buprenorphine\/naloxone treatment is a promising possibility for patients in need of opiatesubstitution treatment.<\/p>\n<p class=\"art\">\n<div class=\"artbody\">\n<p><em>(Neuropsychopharmacol Hung 2012; 14(1): 7-17; doi: 10.5706\/nph201203001)<\/em><\/p>\n<p><em><\/em><\/p>\n<div><strong>Keywords<\/strong>: Problematic drug use, behavioural and psychiatric disorder, recovery, substitution<\/div>\n<\/div>\n<p>[\/et_pb_toggle][et_pb_blurb title=&#8221;Achetylcholinesterase (AChE) inhibition and serum lipokines in Alzheimer\u2019s disease: friend or foe?&#8221; url=&#8221;https:\/\/mppt.hu\/magazin\/pdf\/xiv-evfolyam-1-szam\/kovacs.pdf&#8221; url_new_window=&#8221;on&#8221; image=&#8221;https:\/\/mppt.hu\/wp-content\/uploads\/2019\/04\/pdf.png&#8221; icon_placement=&#8221;left&#8221; image_max_width=&#8221;105%&#8221; content_max_width=&#8221;1100px&#8221; _builder_version=&#8221;3.22.7&#8243; header_font=&#8221;||||||||&#8221; header_font_size=&#8221;17px&#8221; header_line_height=&#8221;1.3em&#8221; body_font=&#8221;||on||||||&#8221; body_line_height=&#8221;1.3em&#8221; link_option_url=&#8221;https:\/\/mppt.hu\/magazin\/pdf\/xiv-evfolyam-1-szam\/kovacs.pdf&#8221; link_option_url_new_window=&#8221;on&#8221;]<\/p>\n<p>J\u00e1nos Kov\u00e1cs, Magdolna P\u00e1k\u00e1ski, Anna Juh\u00e1sz, \u00c1gnes Feh\u00e9r, Gergely Dr\u00f3tos, Csilla Fazekas \u00d6rsike, L\u00e1szl\u00f3 Tam\u00e1s Horv\u00e1th , Zolt\u00e1n\u00a0 Janka and J\u00e1nos K\u00e1lm\u00e1n<\/p>\n<p>[\/et_pb_blurb][et_pb_toggle title=&#8221;Abstract&#8221; closed_toggle_text_color=&#8221;#000000&#8243; closed_toggle_background_color=&#8221;rgba(0,0,0,0)&#8221; icon_color=&#8221;#0c71c3&#8243; _builder_version=&#8221;4.6.6&#8243; title_font=&#8221;|600|||||||&#8221; title_letter_spacing=&#8221;1px&#8221; text_orientation=&#8221;justified&#8221; custom_padding=&#8221;0px||10px&#8221; border_width_all=&#8221;0px&#8221; border_width_bottom=&#8221;1px&#8221;]<\/p>\n<p class=\"art\"><span style=\"color: #666666; font-size: 14px;\">Throughout the natural progression of Alzheimer\u2019s disease (AD), the body mass index (BMI)<br \/> decreases. This is believed to be brought on by the disturbance in the central lipid metabolism, but the exact mechanism is yet unknown. Adipokines (adiponectin, leptin), hormones<br \/> produced by the adipose tissue, change glucose and lipid metabolism, and have an anorectic<br \/> effect through increasing energy consumption in the hypothalamus. The goal of our study was<br \/> to examine donepezil \u2013 an acetylcholinesterase inhibitor (AChEI) currently used in AD therapy \u2013,<br \/> and to what degree it influences the serum adipokine levels and metabolic parameters of AD<br \/> patients. During the self-evaluation of 26 clinically diagnosed mild to moderate AD patients,<br \/> therapy with 10 mg\/day donepezil was started according to current protocols. We measured<br \/> serum adiponectin, leptin, LDL, HDL, trigliceride levels, and BMI and ApoE polymorphism at the<br \/> beginning of our study, and at 3 and 6-months intervals respectively. All data were analyzed<br \/> with SPSS 17. In comparison with pre-donepezil therapy values, at the third month interval<br \/> serum adiponectin levels showed an increasing and leptin levels a decreasing tendency. At the<br \/> six month interval, adiponectin levels significantly increased (p=0.007), leptin levels decreased<br \/> (p=0.013), BMI (p&lt;0.001) and abdominal circumference (p=0.017) was significantly lower at 6<br \/> months as compared to control values. We did not observe any changes in the lipid profile, and<br \/> ApoE4 allele carrying showed no association with the parameters. To our knowledge, we are<br \/> the first to publish that AChEI therapy with donepezil alters lipokine levels, which positively<br \/> influences the currently known pathomechanism and numerous risk factors of AD. The AChEI<br \/> treatment-induced weight loss should be considered in the long-term therapy of AD patients.\u00a0<\/span><\/p>\n<p class=\"art\"><span style=\"color: #666666; font-size: 14px;\"><\/span><\/p>\n<div class=\"artbody\">\n<p><em>(Neuropsychopharmacol Hung 2012; 14(1): 19-27; doi: 10.5706\/nph201203002)<\/em><\/p>\n<p><strong>Keywords<\/strong>: Alzheimer\u2019s disease, dementia, donepezil, lipokine, adiponectin, leptin,<br \/> apolipoprotein E, bodyweight, lipid<\/p>\n<\/div>\n<p>[\/et_pb_toggle][et_pb_blurb title=&#8221;The \u201cblue\u201d side of glutamatergic neurotransmission: NMDA receptor antagonists as possible novel therapeutics for major depression&#8221; url=&#8221;https:\/\/mppt.hu\/magazin\/pdf\/xiv-evfolyam-1-szam\/szakacs.pdf&#8221; url_new_window=&#8221;on&#8221; image=&#8221;https:\/\/mppt.hu\/wp-content\/uploads\/2019\/04\/pdf.png&#8221; icon_placement=&#8221;left&#8221; image_max_width=&#8221;105%&#8221; content_max_width=&#8221;1100px&#8221; _builder_version=&#8221;3.22.7&#8243; header_font=&#8221;||||||||&#8221; header_font_size=&#8221;17px&#8221; header_line_height=&#8221;1.3em&#8221; body_font=&#8221;||on||||||&#8221; body_line_height=&#8221;1.3em&#8221; link_option_url=&#8221;https:\/\/mppt.hu\/magazin\/pdf\/xiv-evfolyam-1-szam\/szakacs.pdf&#8221; link_option_url_new_window=&#8221;on&#8221;]<\/p>\n<p>Reka Szakacs, Zoltan Janka and Janos Kalman<\/p>\n<p>[\/et_pb_blurb][et_pb_toggle title=&#8221;Abstract&#8221; closed_toggle_text_color=&#8221;#000000&#8243; closed_toggle_background_color=&#8221;rgba(0,0,0,0)&#8221; icon_color=&#8221;#0c71c3&#8243; _builder_version=&#8221;3.22.7&#8243; title_font=&#8221;|600|||||||&#8221; title_letter_spacing=&#8221;1px&#8221; text_orientation=&#8221;justified&#8221; custom_padding=&#8221;0px||10px&#8221; border_width_all=&#8221;0px&#8221; border_width_bottom=&#8221;1px&#8221;]<\/p>\n<div class=\"artbody\">\n<p>In spite of the wide-ranging, continuously expanding arsenal of antidepressants and intensive research on depression, the treatment of severe, recurrent mood disorders as well as antidepressant-resistant refractory mood disturbances has not yet entirely been solved. In this article we attempt to review some data from the growing body of evidence that underlie the presumed implication of the glutamatergic neurotransmission in severe mood disorders and thereby some strategies allowing reinstatement of the normal functioning of the glutamatergic system, particularly through N-methyl-d-aspartate (NMDA) receptors. Thus, here we focus on one of the most promising ones, the NMDA receptor-modulating agents including competitive NMDA antagonists, glycine site partial antagonists and channel site antagonists: high- and low-affinity non-competitive NMDA receptor blockers. The glutamate-modulating therapies that specifically affect this system, above all low-affinity non-competitive NMDA receptor antagonists such as amantadine and its derivative memantine which are clinically well tolerated and currently used in other indications hold considerable promise for the development of new, improved antidepressants to treat severe, recurrent and refractory mood disorders.<\/p>\n<p><em>(Neuropsychopharmacol Hung 2012; 14(1): 29-40; doi: 10.5706\/nph201203003)<\/em><\/p>\n<p><strong>Keywords:<\/strong>\u00a0mood disorders, depression, glutamatergic neurotransmission, NMDA antagonists, antidepressant<\/p>\n<\/div>\n<p>[\/et_pb_toggle][et_pb_blurb title=&#8221;Economic recession, unemployment and suicide&#8221; url=&#8221;https:\/\/mppt.hu\/magazin\/pdf\/xiv-evfolyam-1-szam\/duleba%20web.pdf&#8221; url_new_window=&#8221;on&#8221; image=&#8221;https:\/\/mppt.hu\/wp-content\/uploads\/2019\/04\/pdf.png&#8221; icon_placement=&#8221;left&#8221; image_max_width=&#8221;105%&#8221; content_max_width=&#8221;1100px&#8221; _builder_version=&#8221;3.22.7&#8243; header_font=&#8221;||||||||&#8221; header_font_size=&#8221;17px&#8221; header_line_height=&#8221;1.3em&#8221; body_font=&#8221;||on||||||&#8221; body_line_height=&#8221;1.3em&#8221; link_option_url=&#8221;https:\/\/mppt.hu\/magazin\/pdf\/xiv-evfolyam-1-szam\/duleba web.pdf&#8221; link_option_url_new_window=&#8221;on&#8221;]<\/p>\n<p>T\u00edmea Duleba, X\u00e9nia Gonda, Zolt\u00e1n Rihmer, and P\u00e9ter D\u00f6me<\/p>\n<p>[\/et_pb_blurb][et_pb_toggle title=&#8221;Abstract&#8221; closed_toggle_text_color=&#8221;#000000&#8243; closed_toggle_background_color=&#8221;rgba(0,0,0,0)&#8221; icon_color=&#8221;#0c71c3&#8243; _builder_version=&#8221;4.6.6&#8243; title_font=&#8221;|600|||||||&#8221; title_letter_spacing=&#8221;1px&#8221; text_orientation=&#8221;justified&#8221; custom_padding=&#8221;0px||10px&#8221; border_width_all=&#8221;0px&#8221; border_width_bottom=&#8221;1px&#8221;]<\/p>\n<p class=\"art\"><span style=\"color: #666666; font-size: 14px;\">Considering the ongoing global economic crisis which began in 2007 it is reasonable to<br \/> discuss its possible and expectable effects on mental health. In our narrative review we<br \/> have summarized the scientific literature on the relationship between economic downturns,<br \/> unemployment and suicide rate. In addition, we have summarized the theories about the<br \/> background of this relationship as well. Suicide is an extremely complex phenomenon since<br \/> it is influenced by several environmental and genetic factors. Furthermore, some of these factors are mutually interrelated, so the independent effect of these frequently remains elusive<br \/> and hard to investigate from a methodological point of view. Although results are somewhat<br \/> contradictory, it seems that unemployment is an independent risk factor for both suicide<br \/> and depression. The first papers about the effect of the current economic crisis on suicide<br \/> rates have been published and their results confirmed the association between the rise of<br \/> unemployment rate and the increase of suicide rate in both old and new members of the<br \/> European Union. Although psychiatric, and primarily depressive illness is a major risk factor<br \/> for suicide, understanding the contributing role of other etiologic factors in their complex<br \/> relationship may be an important task in predicting and preventing suicide both at the level<br \/> of at risk individuals and the whole population.\u00a0<\/span><\/p>\n<p class=\"art\"><span style=\"color: #666666; font-size: 14px;\"><\/span><\/p>\n<div class=\"artbody\">\n<p><em>(Neuropsychopharmacol Hung 2012; 14(1): 41-50; doi: 10.5706\/nph201203004)<\/em><\/p>\n<p><strong>Keywords<\/strong>: unemployment, economic recession, suicide, depression<\/p>\n<\/div>\n<p>[\/et_pb_toggle][et_pb_blurb title=&#8221;Adulthood \u2013 childhood \u2013 adulthood: Long-term treatment in child and adolescent psychiatry &#8221; url=&#8221;https:\/\/mppt.hu\/magazin\/pdf\/xiv-evfolyam-1-szam\/balazs.pdf&#8221; url_new_window=&#8221;on&#8221; image=&#8221;https:\/\/mppt.hu\/wp-content\/uploads\/2019\/04\/pdf.png&#8221; icon_placement=&#8221;left&#8221; image_max_width=&#8221;105%&#8221; content_max_width=&#8221;1100px&#8221; _builder_version=&#8221;3.22.7&#8243; header_font=&#8221;||||||||&#8221; header_font_size=&#8221;17px&#8221; header_line_height=&#8221;1.3em&#8221; body_font=&#8221;||on||||||&#8221; body_line_height=&#8221;1.3em&#8221; link_option_url=&#8221;https:\/\/mppt.hu\/magazin\/pdf\/xiv-evfolyam-1-szam\/balazs.pdf&#8221; link_option_url_new_window=&#8221;on&#8221;]<\/p>\n<p>Judit Bal\u00e1zs, Judit Tolna, J\u00falia\u00a0 G\u00e1doros and Gy\u00f6ngyv\u00e9r Dallos<\/p>\n<p>[\/et_pb_blurb][et_pb_toggle title=&#8221;Abstract&#8221; closed_toggle_text_color=&#8221;#000000&#8243; closed_toggle_background_color=&#8221;rgba(0,0,0,0)&#8221; icon_color=&#8221;#0c71c3&#8243; _builder_version=&#8221;3.22.7&#8243; title_font=&#8221;|600|||||||&#8221; title_letter_spacing=&#8221;1px&#8221; text_orientation=&#8221;justified&#8221; custom_padding=&#8221;0px||10px&#8221; border_width_all=&#8221;0px&#8221; border_width_bottom=&#8221;1px&#8221;]<\/p>\n<div class=\"autors\">\n<p>&nbsp;<\/p>\n<\/div>\n<div class=\"artbody\">\n<p>The aggregation of psychiatric disorders within families is well-known. The relative role of<br \/>biological, psychogenic and socialization-related factors varies with the individual case.<br \/>Another well-known fact is that parents play a very important role in influencing whether their<br \/>child gets the right treatment when it is necessary. In this paper we highlight the complex<br \/>links between childhood and adulthood through the presentation of three psychiatric cases.<br \/>The first story starts with a lactation psychosis of a mother and ends when the daughter who<br \/>became psychotic at the age of 15 enters adulthood. During these 18 years several psychiatrically relevant episodes happened in the family. During our care, step by step, in relation<br \/>to emerging psychological problems, the family revealed more and more secrets, explaining<br \/>past events, and offering a possibility for psychoeducation and psychotherapy. Knowledge<br \/>concerning the life and psychiatric history of parents, in spite of the fears of the family, largely<br \/>contributed to evaluating the symptoms of the daughter, reaching a diagnosis, initiating and<br \/>maintaining therapy and achieving the present balanced state. The next two cases present the<br \/>stories of two boys with Attention-Deficit\/Hyperactivity Disorder (ADHD). One of the children<br \/>was 6 years old when the family sought professional help, and now he is 11, the other child<br \/>was 8 years old when the parents sought help and he is 15 now. The two families reacted differently to the offered treatment, but in both cases the family stayed continuously in touch<br \/>with their child psychiatrists. With these two different stories on ADHD we would like to present<br \/>several issues and successes which may surface during the long-term treatment of ADHD.\u00a0<\/p>\n<p><em>(Neuropsychopharmacol Hung 2012; 14(1): 51-58; doi: 10.5706\/nph201203005)<\/em><\/p>\n<p><strong>Keywords<\/strong>: Childhood, Adulthood, Psychosis, Attention-Deficit\/Hyperactivity Disorder (ADHD)<\/p>\n<\/div>\n<p>[\/et_pb_toggle][\/et_pb_column_inner][\/et_pb_row_inner][\/et_pb_column][et_pb_column type=&#8221;1_4&#8243; _builder_version=&#8221;3.25&#8243; custom_padding=&#8221;|||&#8221; custom_padding__hover=&#8221;|||&#8221;][et_pb_image src=&#8221;https:\/\/mppt.hu\/wp-content\/uploads\/2019\/05\/cimlap-2012-marcius-kicsi.jpg&#8221; align_tablet=&#8221;center&#8221; align_phone=&#8221;&#8221; align_last_edited=&#8221;on|desktop&#8221; _builder_version=&#8221;3.23&#8243; box_shadow_style=&#8221;preset3&#8243;][\/et_pb_image][\/et_pb_column][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>VOLUME 14, ISSUE 1, MARCH 2012Zsolt Petke, J\u00f3zsef Csorba, Judit M\u00e9sz\u00e1ros, Istv\u00e1n Vingender, Judit Farkas, Zsolt Demetrovics, Zsuzsanna Kov\u00e1cs, Zsuzsa Menczel, Zolt\u00e1n Pataki, P\u00e9ter Simor, Anna Havasi, Katalin Melles, Ferenc\u00a0 M\u00e1rv\u00e1nyk\u00f6vi and J\u00f3zsef R\u00e1czAims: The main target of our research was to measure the changes in psychological symptoms (anxiety, depression, craving) of patients receiving buprenorphine-naloxone [&hellip;]<\/p>\n","protected":false},"author":4,"featured_media":48317,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"project_category":[63],"project_tag":[],"class_list":["post-49327","project","type-project","status-publish","has-post-thumbnail","hentry","project_category-2012-en"],"_links":{"self":[{"href":"https:\/\/mppt.hu\/en\/wp-json\/wp\/v2\/project\/49327","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/mppt.hu\/en\/wp-json\/wp\/v2\/project"}],"about":[{"href":"https:\/\/mppt.hu\/en\/wp-json\/wp\/v2\/types\/project"}],"author":[{"embeddable":true,"href":"https:\/\/mppt.hu\/en\/wp-json\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/mppt.hu\/en\/wp-json\/wp\/v2\/comments?post=49327"}],"version-history":[{"count":8,"href":"https:\/\/mppt.hu\/en\/wp-json\/wp\/v2\/project\/49327\/revisions"}],"predecessor-version":[{"id":49696,"href":"https:\/\/mppt.hu\/en\/wp-json\/wp\/v2\/project\/49327\/revisions\/49696"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/mppt.hu\/en\/wp-json\/wp\/v2\/media\/48317"}],"wp:attachment":[{"href":"https:\/\/mppt.hu\/en\/wp-json\/wp\/v2\/media?parent=49327"}],"wp:term":[{"taxonomy":"project_category","embeddable":true,"href":"https:\/\/mppt.hu\/en\/wp-json\/wp\/v2\/project_category?post=49327"},{"taxonomy":"project_tag","embeddable":true,"href":"https:\/\/mppt.hu\/en\/wp-json\/wp\/v2\/project_tag?post=49327"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}